Abstract: Technical Problem The purpose of the present invention is to provide a method which enables sex selection in a non-human animal, and enables a coming individual to have no recombination gene, and a transgenic non-human animal giving birth to individuals of only one sex, which is used in the method. Solution to Problem The present disclosure relates to a male transgenic non-human animal in which one of an X chromosome and a Y chromosome comprises an exogenous embryonic death induction gene operatively connected to a drug-responsive promoter. The present disclosure also includes a method for producing a male transgenic non-human animal for sex selection.

Abstract: A battery pack includes a battery stack, gas discharge valves, a housing and a metal plate. The battery stack includes plural battery cells arrayed in a thickness direction. The gas discharge valves are provided at top walls of the battery cells and discharge gas that is produced inside the battery cells. The housing is fabricated of resin and accommodates the battery stack in a hermetically sealed state. The metal plate is disposed inside the housing and opposes the gas discharge valves in a vertical direction.

Abstract: A battery stack including: plural battery cells that have been waterproofed, that are arrayed along a horizontal direction, and that each has a length direction running in a direction orthogonal to an array direction of the battery cells; and plural resin frames that are respectively provided between mutually adjacent battery cells, that support both length direction end portions of the battery cells, and that form an opening that exposes lower faces of the battery cells.

Abstract: A laminated substrate includes: a first substrate; a second substrate having a through-hole; a third substrate; a first adhesive layer bonding a rear surface of the first substrate and a front surface of the second substrate; a second adhesive layer bonding a rear surface of the second substrate and a front surface of the third substrate; a first post penetrating through the first adhesive layer, electrically connecting the first substrate to the second substrate, and made of an alloy of a high melting point metal and a low melting point metal; a second post penetrating through the second adhesive layer, electrically connecting the second substrate to the third substrate, and made of an alloy of the high melting point metal and the low melting point metal; and an electronic component fixed to the front surface of the third substrate and disposed in the through-hole of the second substrate.

Abstract: A laminated substrate includes: a first substrate; a second substrate having a through-hole; a third substrate; a first adhesive layer bonding a rear surface of the first substrate and a front surface of the second substrate; a second adhesive layer bonding a rear surface of the second substrate and a front surface of the third substrate; a first post penetrating through the first adhesive layer, electrically connecting the first substrate to the second substrate, and made of an alloy of a high melting point metal and a low melting point metal; a second post penetrating through the second adhesive layer, electrically connecting the second substrate to the third substrate, and made of an alloy of the high melting point metal and the low melting point metal; and an electronic component fixed to the front surface of the third substrate and disposed in the through-hole of the second substrate.

Abstract: A bonding material disclosed in this specification contains high melting point metal particles, low melting point metal particles, and a thermosetting flux resin. A mass proportion of the high melting point metal particles with respect to a total mass of the high melting point metal particles and the low melting point metal particles is 55% to 75%.

Abstract: The present invention relates to a novel 3-aminobenzamide, compound represented by the following formula which effectively inhibits vanilloid receptor subtype 1 (VR1) activity (wherein, for example, R1 is a C1-6 alkyl group which may be substituted, R2 is a hydrogen atom, a C1-6 alkyl group or a C1-6 alkoxy group which may be substituted, R3 is a hydrogen atom or a C1-6 alkyl group, R4 is a C1-6 alkyl group, a C1-6 alkoxy group, or a halo C1-6 alkyl group, m is an integer of 1 to 5 and P is a carbon or hetero ring) or a pharmaceutically acceptable salt thereof. The pharmaceutical composition comprising as active ingredients the 3-aminobenzamide, compound or a pharmaceutically acceptable salt thereof is useful for treating diseases involved in VR1 activity such as pain, acute pain, chronic pain, neuropathicpain, rheumatoid arthritis pain, and neuralgia.

Abstract: A 3,4-dihydrobenzoxazine compound of the present invention is represented by the following formula [1] (wherein X is a nitrogen atom or CR3; R1 is a hydrogen atom or a halogen atom; R2 is a C1-6 alkoxy group which may be substituted with the same or different 1 to 5 substituents selected from a halogen atom and a hydroxyl group; and R3 is a halogen atom. However, R1 is a halogen atom when X is CR3). This compound is effective in treating diseases to which the vanilloid receptor subtype 1 (VR1) activity is involved, such as pain, etc.

Abstract: To provide a compound having an excellent inhibitory effect on vanilloid receptor subtype 1 (VR1) activity which is effective in treating diseases to which the vanilloid receptor subtype 1 (VR1) activity is involved, such as pain, acute pain, chronic pain, neuropathic pain, rheumatoid arthritis pain, neuralgia, etc. and a pharmaceutical composition containing the compound.

Abstract: A 3,4-dihydrobenzoxazine compound of the present invention is represented by the following formula [1] (wherein X is a nitrogen atom or CR3; R1 is a hydrogen atom or a halogen atom; R2 is a C1-6 alkoxy group which may be substituted with the same or different 1 to 5 substituents selected from a halogen atom and a hydroxyl group; and R3 is a halogen atom. However, R1 is a halogen atom when X is CR3). This compound is effective in treating diseases to which the vanilloid receptor subtype 1 (VR1) activity is involved, such as pain, etc.

Abstract: The present invention relates to a novel 3-aminobenzamide compound represented by the following formula which effectively inhibits vanilloid receptor subtype 1 (VR1) activity (wherein, for example, R1 is a C1-6 alkyl group which may be substituted, R2 is a hydrogen atom, a C1-6 alkyl group or a C1-6 alkoxy group which may be substituted, R3 is a hydrogen atom or a C1-6 alkyl group, R4 is a C1-6 alkyl group, a C1-6 alkoxy group, or a halo C1-6 alkyl group, m is an integer of 1 to 5 and P is a carbon or hetero ring) or a pharmaceutically acceptable salt thereof. The pharmaceutical composition comprising as active ingredients the 3-aminobenzamide compound or a pharmaceutically acceptable salt thereof is useful for treating diseases involved in VR1 activity such as pain, acute pain, chronic pain, neuropathic pain, rheumatoid arthritis pain, and neuralgia.

Abstract: A 3,4-dihydrobenzoxazine compound of the present invention is represented by the following formula [1] (wherein X is a nitrogen atom or CR3; R1 is a hydrogen atom or a halogen atom; R2 is a C1-6 alkoxy group which may be substituted with the same or different 1 to 5 substituents selected from a halogen atom and a hydroxyl group; and R3 is a halogen atom. However, R1 is a halogen atom when X is CR3). This compound is effective in treating diseases to which the vanilloid receptor subtype 1 (VR1) activity is involved, such as pain, etc.

Abstract: The present invention relates to a novel 3-aminobenzamide compound represented by the following formula which effectively inhibits vanilloid receptor subtype 1 (VR1) activity (wherein, for example, R1 is a C1-6 alkyl group which may be substituted, R2 is a hydrogen atom, a C1-6 alkyl group or a C1-6 alkoxy group which may be substituted, R3 is a hydrogen atom or a C1-6 alkyl group, R4 is a C1-6 alkyl group, a C1-6 alkoxy group, or a halo C1-6 alkyl group, m is an integer of 1 to 5 and P is a carbon or hetero ring) or a pharmaceutically acceptable salt thereof. The pharmaceutical composition comprising as active ingredients the 3-aminobenzamide compound or a pharmaceutically acceptable salt thereof is useful for treating diseases involved in VR1 activity such as pain, acute pain, chronic pain, neuropathic pain, rheumatoid arthritis pain, and neuralgia.

Abstract: To provide a compound having an excellent inhibitory effect on vanilloid receptor subtype 1 (VR1) activity which is effective in treating diseases to which the vanilloid receptor subtype 1 (VR1) activity is involved, such as pain, acute pain, chronic pain, neuropathic pain, rheumatoid arthritis pain, neuralgia, etc. and a pharmaceutical composition containing the compound.

Abstract: A three-dimensional display comprising a flat light source, a vertical striped filter having slits transmitting light from the light source and barriers screening the light from the light source alternately formed therein for partially transmitting the light from the light source, and an LCD panel arranged on the light emission side of the vertical striped filter and having left eye pixels and right eye pixels alternately formed therein, light passing through the left eye pixels in the LCD panel and light passing through the right eye pixels being emitted toward a observer in a separated state.

Abstract: The 2-D/3-D compatible type image display according to the present invention is constructed by arranging a liquid crystal panel which is a display panel, a dispersed type liquid crystal panel which is a diffusing effect on/off panel, a light separating means, a backlight which is a plane light source, so as to be nearer to an observer in this order. It is possible by processing the image signal supplied to the liquid crystal panel to form a first group of pixels lined in longitudinal direction of a picture and a second group of pixels lined in the same direction of the picture alternately formed in horizontal direction, and to make the first group of pixels and the second group of pixels have different observing points respectively as left eye pixels and right eye pixels (when 3-D images are displayed), or to make the first group of pixels and the second group of pixels have the same observing points with each other (when 2-D images are displayed).

Abstract: The present invention is directed to a three-dimensional display panel capable of viewing a three-dimensional image without using special glasses. The three-dimensional display panel comprises an image display panel having a column of right eye pixels arranged with predetermined spacing in the longitudinal direction on a screen and a column of left eye pixels arranged with predetermined spacing in the longitudinal direction on the screen and so adapted that the column of right eye pixels and the column of left eye pixels are arranged alternately in close proximity to each other in the horizontal direction on the screen and are shifted from each other in the longitudinal direction on the screen to ensure a region where means for switching the respective pixels is formed, and image separating means for separating light from the right eye pixels and light from the left eye pixels to be respectively incident on the right eye and the left eye of a viewer.

Abstract: A flat display includes a closed vessel having a front panel (optically transparent) and a back panel, apparatus for emitting electrons by field emission positioned on the back panel, an anode having an anode electrode and at least a phosphor layer positioned on the front panel, and a spacer for defining a distance between the front panel and the back panel. The spacer has an upper cross-section adjacent to the front panel and a lower cross-section adjacent to the back panel. The lower cross-section is larger than the upper cross-section.

Abstract: A liquid crystal projector includes a light source, a color filter for adding color projection image, a liquid crystal panel for forming a projection image on it, a projection lens and an optical unit located between the color filter and the liquid crystal panel for optically coupling the color filter and the liquid crystal panel. The color filter is separately located from the liquid crystal, and therefore the increase in temperature on the color filter because of absorbing the light from the light source has less effect on the liquid crystal panel.

Abstract: Fluorine is recovered as calcium fluoride from a fluoroetchant solution composed mainly of hydrogen fluoride and ammonium fluoride using a sealed reaction tank equipped with a supply port for adding the fluoroetchant solution to the tank, a supply port for adding calcium carbonate to the tank, a vapor supply port for adding steam to heat the solution in the tank, an air supply port for providing air to aerate the contents of the tank, a stirrer for stirring the contents of the tank, an ejector for removing vapors from the tank connected to the tank via a mist separator for separating mist from the vapors being removed from the tank, and an exhaust port for removing calcium fluoride from the tank.